0.00Open0.02Pre Close0 Volume42 Open Interest95.00Strike Price0.00Turnover5691.50%IV21.66%PremiumNov 22, 2024Expiry Date0.00Intrinsic Value100Multiplier-5DDays to Expiry0.02Extrinsic Value100Contract SizeAmericanOptions Type0.0079Delta0.0028Gamma3905.00Leverage Ratio-56.8044Theta0.0000Rho30.99Eff Leverage0.0000Vega
DexCom Stock Discussion
Revenue came in at $994.2 million, topping the forecast of $990.71 million and showing growth from last year's $975 million.
The company announced that Teri Lawver, EVP and Chief Commercial Officer, will retire by year-end, with CEO Kevin Sayer temporarily leading the commercial team.
DexCom reaffirmed its 2024 sales outl...
Great products sells itself, ask novo disk and how they sell ozempic
No comment yet